Edward Nash
Stock Analyst at Canaccord Genuity
(3.82)
# 741
Out of 4,734 analysts
71
Total ratings
46.77%
Success rate
10.95%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Edward Nash
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APGE Apogee Therapeutics | Initiates: Buy | $89 | $37.06 | +140.15% | 1 | Nov 25, 2024 | |
| VRNA Verona Pharma | Maintains: Buy | $37 → $44 | $51.89 | -15.21% | 8 | Nov 5, 2024 | |
| TVTX Travere Therapeutics | Maintains: Buy | $23 → $22 | $18.37 | +19.76% | 8 | Sep 30, 2024 | |
| VTYX Ventyx Biosciences | Maintains: Buy | $15 → $14 | $2.02 | +593.07% | 6 | Aug 12, 2024 | |
| CORT Corcept Therapeutics | Maintains: Buy | $38 → $78 | $55.31 | +41.02% | 5 | Jul 31, 2024 | |
| CRDL Cardiol Therapeutics | Maintains: Buy | $6 → $8 | $1.21 | +561.16% | 3 | May 23, 2024 | |
| AKRO Akero Therapeutics | Maintains: Buy | $59 → $56 | $25.14 | +122.75% | 5 | May 13, 2024 | |
| IVA Inventiva | Maintains: Buy | $12 → $20 | $2.16 | +825.93% | 2 | Apr 8, 2024 | |
| RANI Rani Therapeutics Holdings | Maintains: Buy | $21 → $9 | $1.31 | +587.02% | 1 | Mar 27, 2024 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $338 → $377 | $293.64 | +28.39% | 8 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $8 | $1.72 | +365.12% | 4 | Jul 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $17 | $4.87 | +249.08% | 2 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $48 | $11.21 | +328.19% | 1 | May 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $3 → $2 | $2.28 | -12.28% | 4 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $900 → $180 | $2.90 | +6,106.90% | 2 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $82 | $40.00 | +105.00% | 6 | Jun 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $120 → $80 | $4.33 | +1,747.58% | 3 | Sep 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $48 | $14.05 | +241.64% | 1 | May 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $650 | $5.22 | +12,352.11% | 1 | Nov 8, 2017 |
Apogee Therapeutics
Nov 25, 2024
Initiates: Buy
Price Target: $89
Current: $37.06
Upside: +140.15%
Verona Pharma
Nov 5, 2024
Maintains: Buy
Price Target: $37 → $44
Current: $51.89
Upside: -15.21%
Travere Therapeutics
Sep 30, 2024
Maintains: Buy
Price Target: $23 → $22
Current: $18.37
Upside: +19.76%
Ventyx Biosciences
Aug 12, 2024
Maintains: Buy
Price Target: $15 → $14
Current: $2.02
Upside: +593.07%
Corcept Therapeutics
Jul 31, 2024
Maintains: Buy
Price Target: $38 → $78
Current: $55.31
Upside: +41.02%
Cardiol Therapeutics
May 23, 2024
Maintains: Buy
Price Target: $6 → $8
Current: $1.21
Upside: +561.16%
Akero Therapeutics
May 13, 2024
Maintains: Buy
Price Target: $59 → $56
Current: $25.14
Upside: +122.75%
Inventiva
Apr 8, 2024
Maintains: Buy
Price Target: $12 → $20
Current: $2.16
Upside: +825.93%
Rani Therapeutics Holdings
Mar 27, 2024
Maintains: Buy
Price Target: $21 → $9
Current: $1.31
Upside: +587.02%
Madrigal Pharmaceuticals
Mar 15, 2024
Maintains: Buy
Price Target: $338 → $377
Current: $293.64
Upside: +28.39%
Jul 3, 2023
Assumes: Hold
Price Target: $8
Current: $1.72
Upside: +365.12%
May 19, 2023
Maintains: Buy
Price Target: $16 → $17
Current: $4.87
Upside: +249.08%
May 18, 2023
Initiates: Buy
Price Target: $48
Current: $11.21
Upside: +328.19%
May 17, 2023
Maintains: Hold
Price Target: $3 → $2
Current: $2.28
Upside: -12.28%
Aug 8, 2022
Downgrades: Hold
Price Target: $900 → $180
Current: $2.90
Upside: +6,106.90%
Jun 19, 2020
Maintains: Buy
Price Target: $80 → $82
Current: $40.00
Upside: +105.00%
Sep 13, 2019
Maintains: Hold
Price Target: $120 → $80
Current: $4.33
Upside: +1,747.58%
May 24, 2018
Initiates: Buy
Price Target: $48
Current: $14.05
Upside: +241.64%
Nov 8, 2017
Initiates: Buy
Price Target: $650
Current: $5.22
Upside: +12,352.11%